RYTM - Rhythm Pharmaceuticals reports Q3 results November, 02 2020 08:09 AM Rhythm Pharmaceuticals Inc. Rhythm Pharmaceuticals (RYTM): Q3 GAAP EPS of -$0.77.Cash, cash equivalents and short-term investments of $201.8M.Shares are up 8.9% PM.Press Release For further details see: Rhythm Pharmaceuticals reports Q3 results